Experimental Hematology & Oncology (Aug 2023)

Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium

  • Yuanhong Jiang,
  • Siyu Wu,
  • Rong Li,
  • Jiazheng Yu,
  • Jianyi Zheng,
  • Zeyu Li,
  • Mingyang Li,
  • Kerong Xin,
  • Zhenqun Xu,
  • Shijie Li,
  • Xiaonan Chen

DOI
https://doi.org/10.1186/s40164-023-00430-1
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/111In-J591 and 225Ac-J591, exhibited enhanced therapeutic efficacy in treating patients with CRPC. Furthermore, promising treatment approaches for CRPC included dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab, prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, and protein kinase inhibitor (AKTi)-CAPltello-280. We have summarized the latest CRPC treatment strategies presented at the 2023 ASCO-GU Cancers Symposium, along with recent advances in CRPC clinical trials.

Keywords